Real-world assessment of treatment with extended-release topiramate (Trokendi XR®) and comparison with previous immediate-release topiramate treatment

  • J Comp Eff Res. 2018 Nov;7(11):1095-1105. doi: 10.2217/cer-2018-0074.
Welton O'Neal  1 ,  Elizabeth E Hur  1 ,  Tesfaye Liranso  1 ,  Barry Patel  2
Affiliations
  • 1. Supernus Pharmaceuticals, Inc., 1550 East Gude Drive, Rockville, MD 20850, USA.
  • 2. Indegene TTM, 222 Chastain Meadows Ct #300, Kennesaw, GA 30144, USA (at time of study).
PMID: 30136603 DOI: 10.2217/cer-2018-0074
Abstract

Aim: Examine clinical profile of extended-release topiramate (Trokendi XR®) and compare treatment-emergent adverse events (TEAEs) associated with Trokendi XR versus previous immediate-release topiramate (TPM-IR) treatment.

Patients & methods: Pilot retrospective study analyzing data extracted from medical charts of patients ≥6 years of age prescribed Trokendi XR.

Results: Trokendi XR was the most commonly used to prevent migraine. The most common TEAEs recorded during topiramate treatment were cognitive symptoms (word-finding difficulty, attention/concentration difficulty, slowed thinking), paresthesia, gastrointestinal problems and decreased appetite/weight loss. TEAE incidence was significantly (p < 0.001) lower during Trokendi XR versus previous TPM-IR treatment.

Conclusion: Trokendi XR use and outcomes in clinical practice were consistent with established profile of topiramate. Results supported the potential for better tolerability of Trokendi XR versus TPM-IR.

Keywords
chart review; comparative effectiveness research; topiramate.
Products